Showing results (161-170 of 366) with videos related to
Sort By:
Pageof 37
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 29, 2019
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLCMakoto Nishio, Enriqueta Felip, Sergey Orlov, et al.Lung Cancer (Amsterdam, Netherlands)|August 26, 2019
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancerDaniel Morgensztern, Nina Karaseva, Enriqueta Felip, et al.Cancer Research|May 11, 2017
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and MelanomaAleix Prat, Alejandro Navarro, Laia Paré, et al.Clinical Lung Cancer|April 25, 2022
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for ManagementRemi Veillon, Hiroshi Sakai, Xiuning Le, et al.Scientific Reports|January 4, 2014
Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entityAleix Prat, Barbara Adamo, Cheng Fan, et al.Molecular Oncology|February 28, 2023
Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLCCaterina Carbonell, Joan Frigola, Nuria Pardo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2025
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 StudyMartin Reck, Jyoti D Patel, Jhanelle E Gray, et al.Lung Cancer (Amsterdam, Netherlands)|May 19, 2024
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancerEnriqueta Felip, Giulio Metro, Daniel S W Tan, et al.JTO Clinical and Research Reports|September 25, 2024
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 StudyJoel W Neal, Armando Santoro, Maria Gonzalez-Cao, et al.The Lancet. Oncology|July 10, 2015
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trialJean-Charles Soria, Enriqueta Felip, Manuel Cobo, et al.Pageof 37